miR-221 Suppression Through Nanoparticle-Based miRNA Delivery System for Hepatocellular Carcinoma Therapy and Its Diagnosis as a Potential Biomarker [Corrigendum]

This article refers to:

RETRACTED ARTICLE: miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker

Li F, Wang F, Zhu C, Wei Q, Zhang T, Zhou YL. Int J Nanomedicine. 2018;13:2295–2307.

The authors have advised Figure 2B on page 2301 is incorrect. Due to an error at the time of figure assembly B1 and B2 were duplicated. The correct Figure 2 is shown below.

Figure 2 Characterization and transfection efficiency of nanoparticle/miRNA complexes.

Notes: (A) Typical SEM images of the PLGA nanopartitcles (A1), PEI-modified nanoparticles (A2), and nanoparticle/miRNA complexes (A3); magnification 15,000×. (B) Hydrodynamic diameter distribution of the PLGA nanoparticles (B1), PEI-modified nanoparticles (B2), and nanoparticle/miRNA complexes (B3). (C) Agarose gel electrophoresis assay of miRNA/nanoparticle complexes at different N/P ratios. (D and E) Typical fluorescent images, corresponding bright images, and transfection efficiency of cells transfected with nanoparticle/FAM–miRNA complexes or lipofectamine/FAM–miRNA complexes. The scale bar represents 100 μm; magnification is 200×.

Abbreviations: CON, control; LIPO, lipofectamine; miRNA, microRNA; NP, nanoparticle; PLGA, poly(lactic-co-glycolic) acid; SEM, scanning electron microscopy; PEI, polyethylenimine.

The authors apologize for this error and advise it does not affect the results of the paper.